Mumbai, Nov. 6 -- Formulation sales in India were Rs 4,734.8 crore, registering a growth of 11%. India Formulation sales accounted for 32.9% of total consolidated sales for the quarter.

Formulation sales in the US were $496 million registering a decline of 4.1%. The decline in generics business was offset by growth in Innovative Medicines. US sales accounted for approximately 30.1% of total consolidated sales.

Emerging Markets formulations sales were $325 million for Q2FY26, up by 10.9% and accounted for 19.7% of total consolidated sales.

Formulation sales in Rest of World (RoW) markets were US$ 234 million for Q2FY26, up by 17.7% and accounted for 14.2% of total consolidated sales for the quarter.

Global Innovative Medicines sales we...